Zentalis Pharmaceuticals, Inc. (ZNTL) Financial Statements (2026 and earlier)

Company Profile

Business Address 10275 SCIENCE CENTER DRIVE
SAN DIEGO, CA 92121
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments371,084141,438323,169234,314124,451
Cash and cash equivalent33,90128,03843,06959,71454,951
Short-term investments337,183113,400280,100174,60069,500
Restricted cash and investments    243 
Receivables 5,000 5,8742,377417
Prepaid expense  7471,0189901,021
Other undisclosed current assets9,982354,533121,872112,846219,215
Total current assets:386,066496,718451,933350,770345,104
Noncurrent Assets
Operating lease, right-of-use asset32,52835,91642,37344,6912,520
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization4,6995,8197,7058,1481,099
Long-term investments and receivables   21,21337,495 
Long-term investments   21,21337,495 
Intangible asset, including goodwill, after accumulated amortization  3,7363,7363,73612,536
Goodwill  3,7363,7363,7363,736
Intangible asset, excluding goodwill, after accumulated amortization     8,800
Restricted cash and investments2,6272,6812,6272,6271,320
Deferred income tax assets101    
Other undisclosed noncurrent assets4,3166,8189,7237,0402,976
Total noncurrent assets:44,27154,97087,377103,73720,451
TOTAL ASSETS:430,337551,688539,310454,507365,555
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities52,72569,36756,64743,94428,601
Accounts payable7,43814,92611,24711,5908,661
Accrued liabilities45,28754,44145,40032,35419,940
Total current liabilities:52,72569,36756,64743,94428,601
Noncurrent Liabilities
Long-term debt and lease obligation:    44,459 
Liabilities, other than long-term debt40,42644,93048,6391,6223,577
Deferred income tax liabilities   8531,6222,480
Other liabilities8491,7802,620 1,097
Operating lease, liability39,57743,15045,16644,459 
Total noncurrent liabilities:40,42644,93048,63946,0813,577
Total liabilities:93,151114,297105,28690,02532,178
Equity
Equity, attributable to parent337,186437,284433,803363,954308,582
Common stock7170594541
Additional paid in capital1,390,9521,323,5761,031,462723,593509,339
Accumulated other comprehensive income (loss)5582,194(1,353)(125)36
Accumulated deficit(1,054,395)(888,556)(596,365)(359,559)(200,834)
Equity, attributable to noncontrolling interest  107   
Other undisclosed equity   22152824,795
Total equity:337,186437,391434,024364,482333,377
TOTAL LIABILITIES AND EQUITY:430,337551,688539,310454,507365,555

Income Statement (P&L) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues67,425900   
Sublease income 1,400900   
Gain on disposition of assets for financial service operations7,918    
Gross profit:67,425900   
Operating expenses(258,619)(299,509)(227,287)(216,542)(118,787)
Other undisclosed operating loss (900)   
Operating loss:(191,194)(299,509)(227,287)(216,542)(118,787)
Nonoperating income (expense)
(Investment Income, Nonoperating)
    50,674(556)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes25,50422,6175,987(522)1,239
Loss from continuing operations before equity method investments, income taxes:(165,690)(276,892)(221,300)(166,390)(118,104)
Loss from equity method investments  (16,014)(16,282)(1,831) 
Other undisclosed income from continuing operations before income taxes    3,662 
Loss from continuing operations before income taxes:(165,690)(292,906)(237,582)(164,559)(118,104)
Income tax expense (benefit)(177)601469297(444)
Loss from continuing operations:(165,867)(292,305)(237,113)(164,262)(118,548)
Loss before gain (loss) on sale of properties:(164,262)(118,548)
Other undisclosed net loss    (1,831) 
Net loss:(165,867)(292,305)(237,113)(166,093)(118,548)
Net income attributable to noncontrolling interest 281143077,368707
Net loss available to common stockholders, diluted:(165,839)(292,191)(236,806)(158,725)(117,841)

Comprehensive Income ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(165,867)(292,305)(237,113)(166,093)(118,548)
Other undisclosed comprehensive income (loss)(1,636)3,547(1,228)(161)36
Comprehensive loss:(167,503)(288,758)(238,341)(166,254)(118,512)
Comprehensive income, net of tax, attributable to noncontrolling interest 281143077,368707
Comprehensive loss, net of tax, attributable to parent:(167,475)(288,644)(238,034)(158,886)(117,805)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: